Lucknow Speciality Pharma

Ruxolitinib Tablets 10 mg
Ruxolitinib Tablets is used to treat myelofibrosis (a cancer of the bone marrow in which the bone marrow is replaced by scar tissue and causes decreased blood cell production) To get access, please contact Patient Support Team @ +91 9760014849 / 9555306364 / 9794360370 / 9140551027, Time 9 am - 8 pm IST or send us a request on email (urgent@lucknowpharma.com) / WhatsApp for the same.
Get Access Price
WhatsApp

Ruxolitinib Tablets was approved for medical use in the United States in 2021. It is on the World Health Organization’s List of Essential Medicines.

Ruxolitinib Tablets Available Price In Lucknow Banaras Nepal

Ruxolitinib Tablets

  • Generic Brand Available – Jakavi
  • API – Ruxolitinib Tablets
  • Packaging – 60 Tablets
  • Strength – 10 mg, 20 mg

What is Ruxolitinib Tablets used for?

Ruxolitinib Tablets is used to treat myelofibrosis (a cancer of the bone marrow in which the bone marrow is replaced by scar tissue and causes decreased blood cell production).

Facts of Medicines

Ruxolitinib Tablets 10 mg

STORAGE AND HANDLING

Care should be exercised in the handling of Ruxolitinib Tablets should not be opened or crushed. Store permitted between 20-25°C (68-77°F).

DOSAGE AND ADMINISTRATION
Doses should be individualized based on safety and efficacy. Starting doses. The starting dose of Jakafi is 10 mg given orally twice daily.
Tablets: 5 mg, 10 mg, 15 mg, 20 mg and 25 mg.

ADVERSE REACTIONS
The most common hematologic adverse reactions (incidence > 20%) are thrombocytopenia and anemia. The most common non-hematologic adverse reactions (incidence >10%) are bruising, dizziness and headache.

 WARNINGS AND PRECAUTIONS 

  • Risk of Infection: Assess patients for signs and symptoms of infection and initiate appropriate treatment promptly. Serious infections should
    have resolved before starting therapy with Jakafi.
  • Thrombocytopenia, Anemia and Neutropenia: Manage by dose reduction, or interruption, or transfusion.
  • Risk of Infection: Assess patients for signs and symptoms of infection and initiate appropriate treatment promptly. Serious infections should
    have resolved before starting therapy with Jakafi.
  • Symptom Exacerbation Following Interruption or Discontinuation: Manage with supportive care and consider resuming treatment with Jakafi.
     Risk of Non-Melanoma Skin Cancer: Perform periodic skin examinations.
     Lipid Elevations: Assess lipid levels 8-12 weeks from start of therapy and treat as needed.

FAQs – Medicine Questions

Ruxolitinib Tablets 10 mg
What is the drug ruxolitinib used for?
Ruxolitinib is used to treat myelofibrosis (a cancer of the bone marrow in which the bone marrow is replaced by scar tissue and causes decreased blood cell production).
Is ruxolitinib chemotherapy?

Jakafi is not chemotherapy. It is a targeted treatment that works to help keep the production of blood cells under control.

What is ruxolitinib mechanism of action?
Ruxolitinib falls under the drug class known as Janus kinase inhibitors (JAK Inhibitors). It is an inhibitor of the JAK1 and JAK2 protein kinases and works by competitively inhibiting the ATP-binding catalytic site on JAK1 and JAK2.
Where can I buy Ruxolitinib Tablets?

You can buy Ruxolitinib Tablets from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.

The buyer should check the existing law in their home country before importing the product.

What is the procedure to buy Ruxolitinib Tablets?

Patients can simply fill the order form or can send mail at info@lucknowpharma.com Patients can also send WhatsApp messages to +91-9555306364 We will reply ASAP with the details of the Ruxolitinib Tablets price as well as procurement procedure.

Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.

Is there a generic ruxolitinib?
Jakafi™ Jakafi™ is the trade for the generic drug ruxolitinib. In some cases, health care professionals may use the generic drug name ruxolitinib when referring to the trade name Jakafi™. Drug type: Jakafi™ is a targeted therapy.

NEWS / UPDATES

  1. Novartis Europharm Limited, Electronic medicines compendium (emc), [Revised on Dec 2020] [ Accessed on 30th Nov 2021], https://www.medicines.org.uk/emc/files/pil.4298.pdf
  2. DSM Pharmaceuticals, Inc, US Food and Drug Administration, [Revised on Nov 2011] [ Accessed on 30th Nov 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202192lbl.pdf
  3. Heiko Becker et al; Ruxolitinib; Recent Results in Cancer Research; Published on 2014; Accessed on 30/11/2021; https://pubmed.ncbi.nlm.nih.gov/24756798/
  4. Stefanie Ajayi et al; Ruxolitinib; Recent Results in Cancer Research; Published on 2018; Accessed on 30/11/2021; https://pubmed.ncbi.nlm.nih.gov/30069628/
Alternative Brands For Ruxolitinib Tablets 10 mg In India

To be sold by retail on prescription of a registered oncologist only (ruxolitinib) tablets, for oral use

JAKAVI 20MG TABLET
Mfr: NOVARTIS INDIA LTD